HDAC inhibitors - CHI's third annual conference

Roberto R. Rosato

Research output: Contribution to journalArticlepeer-review

1 Scopus citations


The HDAC Inhibitors meeting, held in Boston, included topics covering new therapeutic developments in the field of HDAC inhibitors. This conference report highlights selected presentations on HDAC inhibitors for the treatment of cancer, inflammation, and neurodegenerative and other CNS diseases. Investigational drugs discussed include several compounds under evaluation by Karus Therapeutics Ltd, OCID-4681 (Orchid Research Laboratories Ltd) and EVP-0334 (EnVivo Pharmaceuticals Inc).

Original languageEnglish (US)
Pages (from-to)13-15
Number of pages3
Issue number1
StatePublished - Jan 1 2010

ASJC Scopus subject areas

  • Pharmacology
  • Drug Discovery


Dive into the research topics of 'HDAC inhibitors - CHI's third annual conference'. Together they form a unique fingerprint.

Cite this